Application of Novel Solid Lipid Nanoparticle (SLN)-Gene Vector Formulations Based on a Dimeric HIV-1 TAT-Peptide in Vitro and in Vivo

By Rudolph Carsten   Schillinger Ulrike   Ortiz Aurora   Tabatt Kerstin   Plank Christian   Müller Rainer H.   Rosenecker Joseph  

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1662-1669

Springer Publishing Company

Access to resources Recommend Favorite

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

By Karlgren Maria   Ahlin Gustav   Bergström Christel   Svensson Richard   Palm Johan   Artursson Per  

Pharmaceutical Research, Vol. 29, Iss. 2, 2012-02 ,pp. : 411-426

Springer Publishing Company

Access to resources Recommend Favorite

Cell based in vitro and ex vivo models in metabolic disease drug discovery: nice to have or critical path?

By Hallén Stefan   Clapham John C  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 4, 2009-04 ,pp. : 417-428

Informa Healthcare

Access to resources Recommend Favorite

Synthesis, characterization and in vitro anti-tumor activities of novel 9-ethyl-9H-purine derivatives

By Ningegowda Raghu   Grover Amit     Ranjith S.   Rangappa Kanchugarakoppal   Priya B.   Nanjunda Swamy S.  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 754-765

Springer Publishing Company

Access to resources Recommend Favorite

In silico Studies Toward the Discovery of Novel Type-II Inhibitors of TrkA: Pharmacophore-based 3D-QSAR Modeling, Database Screening and Molecular Docking

By  

Letters in Drug Design & Discovery, Vol. 13, Iss. 6, 2016-06 ,pp. : 526-538

Bentham Science Publishers

Access to resources Recommend Favorite